Table 1 Antitumour activity of ONYX-015 (intratumoral injection) and radiation therapy in subcutaneous malignant glioma xenografts

From: Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

 

Treatment intratumoral

n

PR a

CR b

TFS c

5 × vol days

TGD d days

P e

IGRG88 (mutant p53)

 Control

PBS

10

0

0

0

12

–

 

 Rx

5 Gyf+PBS

11

0

0

0

27

15

<0.01

 ONYX-015

108 PFU day−1 × 5

10

2

1

1

22

10

<0.05

 ONYX-015+Rx

5 Gyf+108 PFU day−1 × 5

11

8

0

0

42

30

<0.001

IGRG121 (wild-type p53)

 Control

PBS

9

0

0

0

6

–

 

 Rx

5 Gyf+PBS

9

0

0

0

17

11

<0.01

 ONYX-015

107 PFU day−1 × 5

10

0

0

0

11

5

NS

 ONYX-015+Rx

5 Gyf+107 PFU day−1 × 5

10

4

5

5

81

75

<0.001

  1. aPartial regression; bcomplete regression; ctumour-free survival; dtumour growth delay; efor each experiment, the 5 × volumes in the treatment groups were compared to those of the control group using a two-tailed nonparametric Kruskal–Wallis test; ftotal body irradiation.
Back to article page